University of Amsterdam

Laura J. van 't Veer Honored with 2024 William L. McGuire Memorial Lecture Award for Breast Cancer Advancements

7 months ago

• Laura J. van 't Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at the San Antonio Breast Cancer Symposium (SABCS) 2024 for her contributions to breast oncology. • Van 't Veer is recognized for her work in risk stratification and treatment of early breast cancer through the development of MammaPrint. • Her efforts in the I-SPY 2 trials led to the development of biomarkers that predict patient response to specific therapies. • Van 't Veer's research focuses on personalized medicine, aiming to improve patient management using the genetic makeup of tumors.

AI Accelerates Drug Discovery and Clinical Trials, Reducing Time and Costs

8 months ago

• AI is revolutionizing drug discovery by accelerating target identification, drug molecule design, and clinical development, potentially reducing costs and increasing the probability of success in Phase 2 trials. • Generative AI analyzes vast datasets to identify promising drug candidates and predict molecular interactions, while AI-focused biotechs are rapidly advancing drug candidates into clinical trials. • AI is enhancing clinical trial efficiency through automated data analysis, predictive modeling for site selection, improved patient engagement, and faster recruitment, leading to quicker trial completion and reduced participant numbers. • The integration of AI in drug discovery and development promises faster, cheaper, and better-value outcomes by minimizing experimental overhead, improving trial efficiency, and balancing drug properties.